An integrative transcriptomic analyses of aripiprazole effects on differentially expressed genes in COVID-19 patients was performed.įindings: 82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. COVID-19 RNA-Seq samples (CRA002390 project in GSA database) and drug-naïve patients with non-affective psychosis at baseline and after three months of aripiprazole treatment were identified. Methods: Differential gene expression profiles of non-COVID-19 vs. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID-19-related immunological parameters. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. 9Spanish National Research Council (CSIC), Institute of Biomedicine and Biotechnology of Cantabria, Santander, Spainīackground: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes.8Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain.7Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain.6Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University of Seville, Salamanca, Spain.
1Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain.Cisneros 6,7, Carlos Prieto 8 ‡ and Jesus Sainz 9 ‡ Sánchez-Hidalgo 2,5, Nathalia Garrido-Torres 1, Jose M. Benedicto Crespo-Facorro 1,2* †, Miguel Ruiz-Veguilla 1,2 †, Javier Vázquez-Bourgon 2,3,4, Ana C.